Crispr Therapeutics price target lowered to $82 from $89 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...
Zacks.com on MSN18h
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
Morningstar7d
Crispr Earnings: Casgevy Launch Ongoing and Trial Updates Expected in 2025; Positive Outlook
Casgevy, a gene therapy for sickle cell disease and beta thalassemia developed with Vertex Pharmaceuticals, has had a fairly slow rollout, but its launch seems to be gaining momentum. Fifty ...
People living with Sicke Cell apprehensive that new treatment Casgevy is here to stay
People living with sickle cell are apprehensive about a revolutionary new one-off treatment that has just been approved for use on the NHS. | ITV News Granada ...
Seeking Alpha13d
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized ...
China Internet Information Center2d
Bahrain conducts 1st CRISPR-based sickle cell treatment outside U.S.
MANAMA, Feb. 16 (Xinhua) -- Bahrain has achieved a medical milestone by successfully treating a patient with sickle cell disease (SCD) using CRISPR-based gene-editing therapy, Casgevy, the Bahrain ...
UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC's 'Final Trades'
UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.
Morningstar2d
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the first licensed therapy to utilise CRISPR/Cas9 gene-editing technology, whose inventors were awarded the 2020 Nobel ...